Topic: infectious disease
The agreement sees Sanofi transfer 100 employees, more than 10 drug candidates and €60 million upfront to the German service provider.
Vical has yet another drug flop to contend with, giving up on its genital herpes vaccine after earlier failures for CMV and cancer immunotherapies.
Brii Biosciences' mission is to overcome the challenges that have prevented the spread of innovative medicines throughout China.
Genentech and Lodo Therapeutics signed a drug discovery collaboration worth nearly $1 billion, focused on deriving products from DNA found in soil.
Mammoth Biosciences is developing a CRISPR-based platform to detect any biomarker containing DNA or RNA.
Roivant Sciences is adding a late-phase drug to its pipeline: Nabriva's pneumonia antibiotic lefamulin.
Sanofi will license out a host of infectious disease assets to Evotec, with 100 staffers also moving into its R&D engine.
Approval of the Oxford Immunotec tests give the U.S. a way to stop the spread of babesiosis, a life-threatening disease carried by deer ticks.
Three years after its last misfire, Israeli biotech PolyPid is having another go at a Nasdaq listing, seeking $86 million to develop anti-infectives.
The week’s biotech discoveries include an insulin-related gene mutation and the news that previously ignored brain structures could govern obesity.